Cargando…
Review immune response of targeting CD39 in cancer
The ATP-adenosine pathway has emerged as a promising target for cancer therapy, but challenges remain in achieving effective tumor control. Early research focused on blocking the adenosine generating enzyme CD73 and the adenosine receptors A2AR or A2BR in cancer. However, recent studies have shown t...
Autores principales: | Liu, Yao, Li, Zhongliang, Zhao, Xiaoguang, Xiao, Jing, Bi, Jiacheng, Li, Xian-Yang, Chen, Guokai, Lu, Ligong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249319/ https://www.ncbi.nlm.nih.gov/pubmed/37287049 http://dx.doi.org/10.1186/s40364-023-00500-w |
Ejemplares similares
-
CD39 and control of cellular immune responses
por: Dwyer, Karen M., et al.
Publicado: (2007) -
Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
por: Kashyap, Abhishek S., et al.
Publicado: (2019) -
Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses
por: Shevchenko, Ivan, et al.
Publicado: (2020) -
CD39: the potential target in small cell lung cancer
por: Chen, Shanhao, et al.
Publicado: (2020) -
Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39
por: Michaud, Mickaël, et al.
Publicado: (2012)